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Abstract
Combination antiretroviral therapy (cART) can effectively suppress HIV-1 replication, but the latent viral reservoir in resting
memory CD4+ T cells is impervious to cART and represents a major barrier to curing HIV-1 infection. Reactivation of latent
HIV-1 represents a possible strategy for elimination of this reservoir. In this study we describe the discovery of 1,2,9,10-
tetramethoxy-7H-dibenzo[de,g]quinolin-7-one (57704) which reactivates latent HIV-1 in several cell-line models of latency
(J89GFP, U1 and ACH-2). 57704 also increased HIV-1 expression in 3 of 4 CD8+-depleted blood mononuclear cell
preparations isolated from HIV-1-infected individuals on suppressive cART. In contrast, vorinostat increased HIV-1
expression in only 1 of the 4 donors tested. Importantly, 57704 does not induce global T cell activation. Mechanistic studies
revealed that 57704 reactivates latent HIV-1 via the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) signaling
pathway. 57704 was found to be an agonist of PI3K with specificity to the p110a isoform, but not the p110b, d or c isoforms.
Taken together, our work suggests that 57704 could serve as a scaffold for the development of more potent activators of
latent HIV-1. Furthermore, it highlights the involvement of the PI3K/Akt pathway in the maintenance of HIV-1 latency.
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Introduction
Combination antiretroviral therapy (cART) can effectively
suppress HIV-1 RNA levels to below 50 copies mL21 in patient
plasma. However, interruption of cART typically results in
viremia rebound. Therefore, cART does not eliminate HIV-1
infection and residual low-level viremia has been detected using
ultrasensitive assays in 80% of treated patients [1–4]. Latently
infected resting memory CD4+ T cells are thought to constitute the
major reservoir of HIV-1 persistence [5–8]. In this reservoir, the
integrated provirus remains transcriptionally silent as long as the
host cell is in a resting state [9]. Upon cellular activation, HIV-1
RNA is transcribed and virus is produced. The prevailing
hypothesis in the field is that molecules that reactivate latent
HIV-1 infection will purge this reservoir by inducing transcription
of the latent provirus (i.e. the ‘‘kick’’), thereby causing cells to
undergo apoptosis (the ‘‘kill’’) [10]. It should be noted, however,
that in a recent study by Shan et al it was shown that after reversal
of HIV-1 latency in an in vitro model, infected resting CD4+ T cells
survived despite virl cytopathic effects, even in the presence of
autologous cytolytic T lymphocytes from most patients on cART
[26]. Despite this finding, several clinical trials are directly testing
the ‘‘kick and kill’’ hypothesis using agents including the histone
deacetylase (HDAC) inhibitor vorinostat (SAHA) [ClinicalTrials.-
gov Identifiers: NCT01319383 and NCT01365065] or disulfiram
(DSF) [ClinicalTrials.gov Identifier: NCT0047732], a drug used to
treat chronic alcoholism [11]. Encouragingly, recent data from the
NCT01319383 trial showed that a single 400 mg dose of SAHA
induced an increase in HIV-1 RNA expression in resting CD4+ T
cells in 8 HIV-infected patients on suppressive cART [12].
While the ‘‘kick and kill’’ concept currently represents a
promising avenue that could be scaled up for treatment of HIV-
infected patients, the successful implementation of this approach is
limited by the paucity of potent and safe inducers of latent HIV-1
gene expression. Importantly, many of these compounds either
lack potency and specificity or have unfavorable toxicity profiles.
For example, several studies have demonstrated that the latent
HIV-1 reactivation activity of HDAC inhibitors is sub-optimal
(compared to phytohaemagglutinin or anti-CD3/CD28 antibod-
ies) and can vary considerably in resting T cells isolated from
different HIV-1-infected donors [13,14]. Additionally, HDAC
inhibitors typically lack specificity and inhibit multiple HDAC
isoforms (e.g. SAHA is a potent inhibitor of HDACs 1, 2, 3, 6 and
8) [16]. Similarly, the clinical utility of the PKC agonists prostrain
and bryostatin may be limited by their unfavorable toxicity
profiles. Prostratin induces global T cell activation [15], a
phenotype that may induce clinical toxicity. In a recent phase II
clinical trial for the treatment of ovarian cancer, bryostatin was
found to cause severe myalgia in all study participants [17]. As
such, there is an urgent need to develop potent and safe inducers
of latent HIV-1 gene expression that could open new avenues to a
finding a scalable and affordable cure for HIV-infected patients.
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In this study, we described the discovery of 1,2,9,10-tetra-
methoxy-7H-dibenzo[de,g]quinolin-7-one (57704; Fig. 1). 57704
reactivates latent HIV-1 via the phosphatidylinositol 3-kinase
(PI3K)/protein kinase B (Akt) signaling pathway through direct
binding to, and activation of, the PI3K p110a isoform. 57704
could serve as a scaffold for the development of more potent
activators of latent HIV-1.
Materials and Methods
Materials
The natural compound library was purchased from TimTec
(Newark, DE). SAHA was from Enzo Life Sciences (Plymouth
Meeting, PA). Wortmannin, SB203580, SP600125, Go6983, BIX-
01294, cyclosporin A, DSF and prostratin were purchased from
Sigma-Aldrich (St. Louis, MO). The PI3K isoform inhibitors were
from BioVision (Milpitas, CA, USA). The Akt inhibitor IV and the
NF-kB activation inhibitor were obtained from EMD Biosciences
(Gibbstown, NJ). Akt and phospho-AKT were obtained from Cell
Signaling Technology (Boston, MA). The b-actin antibody was
obtained from Abcam (Cambridge, MA). The CD4-APC, CD8-
PerCP, CD69-PE, CD38-PE and HLA-DR-PE antibodies were
purchased from BD Biosciences (San Jose, CA). DNA oligonucle-
otide primers were synthesized by Integrated DNA Technologies
(San Diego, CA). The recombinant purified HDAC isoforms were
purchased from BPS Bioscience (San Diego, CA). Recombinant
purified PI3K isoforms and the PI3K activity assay kit were
purchased from Millipore (Billerica, MA). Cellular proteins were
separated using 4–12% SDS-polyacrylamide gels from Invitrogen
(Grand Island, NY). Immunodetection was performed using the
Millipore SNAP i.d. H (Billerica, MA).
Cell line models of HIV latency
Three different cell lines of HIV-1 latency were used in this
study. These included J89GFP, U1 and ACH-2 cells. The J89GFP
cells were a kind gift from Dr. David Levy [18]. The ACH-2 and
U1 cells were obtained through the AIDS Research and Reference
Reagent Program, Division of AIDS, NIAID, NIH: Dr. Thomas
Folks contributor [19–21]. Reactivation of latent HIV-1 in the
J89GFP cells was measured by quantifying the percentage of
EGFP positive cells using a BD FACScan flow cytometer with BD
FACSDiva software (BD Biosciences, CA), as described previously.
Reactivation of latent HIV-1 in the ACH-2 and U 1 cells was
assessed by quantitative analysis of initiated and elongated HIV-1
transcripts, as described previously [16]. All 3 cell lines were
maintained in RMPI 1640 medium supplemented with 10% FBS,
0.3 mg/mL L-glutamine, 100 U/mL penicillin, and 100 mg/mL
streptomycin at 37uC in humidified air with 5% CO2.
Cytotoxicity measurements
16104 cells were plated in 96-well plates with varying
concentrations of 57704 or SAHA. Following a 24 hour incuba-
tion period, cell viability was measured using either the MTT
(Roche Applied Science, Indianapolis, IN) or CellTiter 96
proliferation (Promega, WI) assay. The concentration of 57704
that decreased cell viability by 50% (i.e. 50% cytotoxic concen-
tration; CC50) was calculated by regression analysis using
SigmaPlot software.
Blood donors
Healthy HIV-1 uninfected blood donors and HIV-1-infected
donors on suppressive cART with plasma HIV-1 RNA less than
50 copies/mL for .2 year provided written informed consent
and underwent a large volume phlebotomy (100–200 mLs).
The protocol for blood donation was approved by the Insti-
tutional Review Board of the University of Pittsburgh (IRB
#PRO10070203).
Isolation of CD8+-depleted blood mononuclear cells
(MNC) and quantitative assessments of HIV-1 RNA
CD8+T-cells were depleted from whole blood using RosetteSep
Human CD8 Depletion Cocktail (StemCell Technologies, Van-
couver, BC) according to manufacturer’s instructions. 26106
CD4+ MNC cells were seeded in triplicate per treatment in 48-well
plates and allowed to rest overnight. All wells were maintained in
81 nM efavirenz. Cells were treated with 57704 (1 or 5 mM),
SAHA (0.5 or 2 mM), or vehicle control (0.1% DMSO). Activation
controls were treated with CD3/CD28 Dynabeads (Life Tech-
nologies, Grand Island, NY). After 7 days of incubation,
supernatants from triplicate wells were pooled, centrifuged
(500 g65 min), and stored at 280uC. HIV-1 RNA levels in
supernatants were determined using the COBASH AmpliPrep/
COBASH TaqManH HIV-1 Test, v2.0 (Roche, Indianapolis, IN).
Evaluation of global T cell activation
Peripheral blood MNC were obtained from the blood of healthy
donors by Ficoll-Paque PLUS (GE Healthcare, Piscataway, NJ)
density gradient centrifugation. T cells were isolated using the Pan
T Cell Isolation kit (Miltenyi Biotec, Auburn, CA) according to
manufacturer’s instruction. Briefly, non-T cells were depleted from
the MNC using biotin-conjugated antibodies to CD14, CD15,
CD16, CD19, CD34, CD36, CD56, CD123, and CD235a and
anti-biotin-labeled magnetic beads. Following exposure to 57704,
SAHA or phytohaemagglutinin (PHA), the cells were washed and
resuspended in 100 ml PBS that contained antibodies (aCD38-PE,
aHLA-DR-FITC, or aCD69-PE) and incubated for 30 min. Cells
were then washed twice with PBS, resuspended in PBS with 4%
PFA and stored in the refrigerator until analysis. Samples were
analyzed on a BD LSRII flow cytometer and analyzed using
FACsDiva software (BD Biosciences, Mountain View, CA).
Forward versus side scatter plot was used to define the live cell
population and fluorescence gates were set based on isotype
control fluorescence.
PI3K activity assays
The production of phosphatidylinositol (3,4,5)-triphosphate
(PIP3) by the four class I PI3K isoenzymes (p110 a, b, c, d) was
assessed using the PI3 Kinase Activity/Inhibitor Assay Kit
Figure 1. Chemical structures of 57704 and SAHA.
doi:10.1371/journal.pone.0084964.g001
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(Millipore, Billerica, MA) according to the manufacturer’s
instructions. This assay works on the principle that the PH
domain of the protein GRP-1 binds PIP3 with high affinity and
specificity. This protein binds to the glutathione plate and captures
either the PIP3 generated as part of the kinase reaction or the
biotinylated-PIP3 tracer included in the kit. The captured
biotinylated-PIP3 is detected using streptavidin-HRP conjugate
and a colorimetric read out (OD 450). Because the signal in this
assay is inversely proportional to the kinase activity, the activity of
Figure 2. Latent HIV-1 reactivation activity of 57704, alone and in combination with other inducing agents, in the U1 and ACH2 cell
line models of virus latency. HIV-1 expression was assessed by quantitative PCR analysis of early and late viral RNA transcripts. Where appropriate,
TNFa was used as an activation control. (A) Latent HIV-1 reactivation of activity 57704 in the J89GFP cell line. An EC50 of 10.361.2 mM was determined
for 57704 in this cell line. (B) Latent HIV-1 reactivation activity of 57704 in the ACH2 cell line. (C) Latent HIV-1 reactivation of activity 57704 in the U1
cell line. (D) Graph of activation of latent HIV-1 early and late gene transcript expression in the ACH2 and U1 cell lines. EC50 values were determined in
Sigma Plot by nonlinear regression, as described previously. (E) Latent HIV-1 reactivation of 5 mM 57704 in combination with 1 mM prostratin in the
U1 cell line. (F) Latent HIV-1 reactivation of 5 mM 57704 in combination with 5 mM SAHA in the U1 cell line. (G) Latent HIV-1 reactivation of 5 mM
57704 in combination with 2.5 mM DSF in the U1 cell line. (H) Latent HIV-1 reactivation of 5 mM 57704 in combination with 20 mM BIX-01294 in the U1
cell line. Data represent the mean 6 standard deviation from 3 replicate experiments.
doi:10.1371/journal.pone.0084964.g002
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57704 was assessed in combination with the pan-PI3K inhibitor
wortmannin.
HDAC activity assays
The lysine deacetylase activity of HDACs 1, 2, 3, and 8 was
assessed using the Fluorogenic HDAC Assay (BPS Bioscience, San
Diego, CA) according to the manufacturer’s instructions. The
HDAC3 used in this assay was complexed with human nuclear
receptor co-repressor 2 (NCOR2; amino acids 395–489), which is
an activating co-factor of this HDAC isoform. All assays were
carried out under steady-state conditions and the assay read-out
was optimized for linearity both as a function of time and enzyme
concentration. The formation of the fluorescent product was
measured using a SpectraMax M2 Plate Reader (Molecular
Devices, CA). The excitation and emission wavelengths were
360 nm and 450 nm, respectively. The concentrations of SAHA
required to inhibit 50% of the deacetylase activity of an HDAC
isoform (i.e. IC50) was calculated by regression analysis using
SigmaPlot software (Systat Software, Inc., San Jose, CA).
Results
Discovery of 57704
To identify novel activators of latent HIV-1 expression, we
screened 640 pure natural products from the TimTec Natural
Compound Library at a concentration of 10 ng/mL for 24 hrs in
a Jurkat cell (J89GFP) model of latency for their cytotoxicity and
ability to reactivate HIV-1 expression. J89GFP cells contain a
stably integrated, full-length HIV-1 provirus with an enhanced
GFP (EGFP) reporter incorporated into the viral genome [18].
The viral genome in these cells is transcriptionally silent. However,
upon stimulation viral transcription is activated and viral
expression can be measured by EGFP production. Seven
compounds (1.1%) were identified that reactivated latent HIV-1
expression, none of which showed significant cytotoxicity at the
single concentration tested (data not shown). Following extensive
analyses in different cell line models of HIV-1 latency we found
that 57704 (Fig. 1) was one of the more robust analogs identified in
the screen. The effective concentration of compound that
reactivated 50% of latent HIV-1 gene expression (i.e. EC50)
ranged from ,5 to 9 mM in the ACH2 and U1 cell lines of virus
latency (Fig. 2B, C, D). By comparison, in J89GFP cells the EC50
was calculated to be 10.361.2 mM (Fig. 2A). The EC50 values for
SAHA ranged from ,1 to 5 mM in the same cell lines (data not
shown). Importantly, 57704 was significantly less cytotoxic than
SAHA in several different cell lines and in CD8+-depleted MNC
(Table 1). Of note, the latent HIV-1 reactivation activity of 57704
was increased in an additive manner when combined with other
inducing agents including prostratin (Fig. 2E), SAHA (Fig. 2F),
DSF (Fig. 2G) and the histone methyltransferase inhibitor BIX-
01294 (Fig. 2H).
57704 increases HIV-1 expression in CD8+-depleted MNC
from HIV-1-infected donors on suppressive cART without
inducing global T cell activation
We compared the activity of 57704 to reactivate latent HIV-1
from CD8+-depleted blood MNC from 4 different cART-treated
individuals with plasma HIV-1 RNA,50 copies/mL (Table 2,
Fig. 3A). SAHA was included as a control. 5 mM 57704 increased
HIV-1 RNA in culture supernatants ,4-fold compared to the
control (Fig. 3A) although significant variability was observed
between donors (Table 2). Specifically, increases in HIV-1 RNA
levels in culture supernatant compared to the vehicle control were
detected in the CD8+-depleted blood MNC from donors 1 and 2
but not in donors 3 and 4. Although the mean supernatant HIV-1
RNA copy number determined for the 4 donors after treatment
with 1 mM 57704 was comparable to that of controls, higher levels
were detected in donors 3 and 4. By contrast, SAHA exhibited a
very limited capacity to increase HIV-1 expression in the CD8+-
depleted MNC across all four donors (Table 2). Since agents that
induce latent HIV-1 through global T cell activation are toxic, we
next assessed the 57704’s capacity to induce this phenotype.
Purified T cells were treated with 10 mg/mL PHA (positive
control), 5 mM SAHA or different concentrations of 57704 for up
to 5 days, and then stained for surface expression of CD69, CD38
and HLA-DR (Fig. 3B, C). 57704 did not up-regulate the surface
expression of any of these markers, even after 5 days of exposure to
drug (Fig. 3C). Taken together, these data indicate that 57704
increases HIV-1 expression in CD8+-depleted MNC from HIV-1-
infected donors without inducing global T cell activation.
Mechanism of action studies
To gain insight into the mechanism by which 57704 reactivates
latent HIV-1, we evaluated its activity in combination with
inhibitors of different signaling pathways or kinases in J89GFP
cells (Fig. 4A, B). We found that the activity of 57704 was
significantly attenuated by the PI3K inhibitor wortmannin, by the
Akt Inhibitor IV, and by the NF-kB inhibitor 6-amino-4-(4-
phenoxyphenylethylamino) quinazoline. By contrast, its activity
was unaffected by the PKC inhibitor Go¨6983, by the c-Jun N-
terminal kinase (JNK) kinase inhibitor SP600125, by the p38
mitogen-activated protein kinase inhibitor SB203580, and by the
NFAT inhibitor cyclosporin A. Consistent with its mechanism of
action, the latent HIV-1 reactivation activity of prostratin was
attenuated when combined with the PKC inhibitor Go¨6983, but
remained unaffected by inhibitors of calcineurin, JNK, PI3K and
Akt (Fig. 4A). Taken together, these data suggested that 57704
reactivated latent HIV-1 via the PI3K/Akt signaling pathway. To
determine whether 57704 directly activated the PI3K/Akt
signaling pathway, we next assessed the levels of Akt phosphor-
ylation in the J89GFP cells after exposure to 5 mM 57704. Western
blot analysis clearly demonstrated that 57704 increased Akt
phosphorylation (Fig. 4C).
Table 1. Cytotoxicity of 57704 and SAHA in different cells.
Compound Jurkat1 CC50 (mM) HeLa
1 CC50 (mM) 293T
1 CC50 (mM) CD8+-depleted MNC2 CC50 (mM)
57704 92.967.5 293.2656.42 105.5631.4 80
SAHA 10.060.1 11.360.3 14.160.2 0.7
1Data represent the mean 6 standard deviation from 3 replicate experiments.
2Data represent the mean from 2 independent replicate experiments.
doi:10.1371/journal.pone.0084964.t001
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The class I PI3Ks are heterodimeric enzymes formed by
association of a p110 catalytic subunit with a p85 regulatoryT
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Figure 3. Latent HIV-1 reactivation activity of 57704 and T cell
activation in CD8+-depleted MNC. (A) Quantitation of cell-free HIV-
1 RNA in the culture supernatants of CD8+-depleted blood MNC
incubated with 57704 or SAHA. (B) Surface expression of CD69, CD38
and HLA-DR after 24 h in purified T cells following exposure to 10 mg/
mL PHA, 57704 or SAHA. (C) Surface expression of CD69, CD38 and HLA-
DR after 5 days in purified T cells following exposure to 10 mg/mL PHA,
57704 or SAHA.
doi:10.1371/journal.pone.0084964.g003
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subunit. There are 4 variants of the p110 catalytic subunit
designated p110a, b, d or c [22]. To determine whether 57704
displayed PI3K isoform specificity, we first assessed its activity in
J89GFP cells in combination with inhibitors specific to each PI3K
isoform (Fig. 4D). We found that 57704’s activity was significantly
attenuated by the pan PI3K inhibitor LY 294002 and by the PI3K
p110a specific inhibitor PI-103. By contrast, its activity was not
reduced by inhibitors of PI3K p110b, p110d or p110c. Of note,
AS-605240 and TGX-221 which target PI3K p110c and p110b,
respectively, moderately enhanced the latent HIV-1 reactivation
activity of 57704. To determine whether 57704 directly impacted
the gene expression levels of the PI3K isoforms, we assessed RNA
transcript levels in J89GFP cells treated with either 57704 or
Figure 4. 57704 reactivates latent HIV-1 via the PI3K/Akt signaling pathway. (A) Latent HIV-1 reactivation activity of prostratin in the
absence (control) or presence of inhibitors of calcineurin (1 mM cyclosporin A), JNK (1 mM SP00125), PI3K (20 nM wortmannin), Akt (500 nM Akt
Inhibitor IV) and PKC (500 nM Go6983). (B) Latent HIV-1 reactivation activity of 57704 in the absence (control) or presence of inhibitors of p38 MAPK
(50 nM SB203580), calcineurin, JNK, PI3K, Akt, PKC and NF-kB (20 mM NF- kB activation inhibitor). (C) Western blot analysis of phosphorylated Akt in
J89GFP treated with 5 mM 57704. (D) Latent HIV-1 reactivation activity of 57704 in the absence (control) or presence of a pan-inhibitor of PI3K (15 mM
LY294002) or inhibitors targeting the p110a (2 mM PI-103), p110d (5 mM IC87114), p110c (2 mM AS-605240) or p110b (2 mM TGX-221) isoforms. (E)
PI3K isoform transcript levels in cells treated with 5 mM 57704 or 5 mM 57704 SAHA.(F) Inhibition of the PI3K p110a, b, d and c isoforms by 100 nM
wortmannin alone or in combination with 5 mM 57704 or 5 mM 57704 SAHA.
doi:10.1371/journal.pone.0084964.g004
Table 3. In vitro activity of 57704 and SAHA against class I
HDAC isoforms.
HDAC Isoform SAHA IC50 (nM) 57704 IC50 (mM)
HDAC1 13.760.15 .50
HDAC2 62.060.15 .50
HDAC3 86960.15 .50
HDAC8 6.860.15 .50
Data represent the mean 6 standard deviation from 3 replicate experiments.
doi:10.1371/journal.pone.0084964.t003
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SAHA (Fig. 4E). We found that 57704 moderately decreased PI3K
p110b RNA levels (,2-fold) but had no effect on p110a, p110d or
p110c. SAHA also moderately decreased PI3K p110b RNA levels
(,2-fold), but was found to significantly up-regulate p110d gene
expression. We next assessed 57704’s activity against recombinant
purified PI3K isoforms using an assay developed by Millipore.
Briefly, in this assay the PIP3 generated as part of the kinase
reaction or the biotinylated-PIP3 tracer included in the kit is
captured on a glutathione plate via its interaction with the
pleckstrin homology (PH) domain of the glutathione S-transferase
(GST)-fusion protein general receptor for phosphoinositides-1
(GRP-1). The captured biotinylated-PIP3 is then detected using a
streptavidin-HRP conjugate and a colorimetric read out. Because
the signal of the assay is inversely proportional to PI3K activity, we
assessed the activity of 57704 in combination with wortmannin.
We found that 57704 acted as an agonist in that it abrogated the
ability of wortmannin to inhibit PI3K p110a (Fig. 4E,F) but not
PI3K p100b, d or c (Fig. 4F). Prior studies demonstrated that
SAHA and other HDAC inhibitors also activated the PI3K/Akt
signaling pathway [16,23]. Therefore, we also assessed the ability
of SAHA to impact the activity of PI3K. Interestingly, SAHA also
acted as an agonist of PI3K p110a. (Fig. 4F) However, it also
activated the PI3K p100b, d and c isoforms (Fig. 4F). In light of
this finding, we next assessed whether 57704 inhibited the activity
of the class I HDAC isoforms, HDAC1, HDAC2, HDAC3 and
HDAC8, using recombinant purified enzymes (Table 3). SAHA
was included as a control in these experiments. 57704 exhibited no
discernable inhibitory activity toward any of the HDAC isoforms
(Table 3).
Discussion
The latent reservoir in resting memory CD4+ T cells represents
a major obstacle towards curing HIV-1 infection. The mecha-
nisms that lead to HIV-1 latency in CD4+ T cells are still not
completely understood. Indeed, there is ample evidence that
multiple restrictions prevent the emergence of virus from latency,
including both cellular and viral factors [24]. Therefore, a better
understanding of the establishment and maintenance of HIV-1
latency and identification of pharmacologic targets will open
avenues to rational therapeutic approaches for clearing infection.
In this study, we show that 57704 – a novel agonist of PI3K
p110a – can reactivate latent HIV-1 in different cell lines of virus
latency and increase HIV-1 expression in CD8+-depleted blood
MNC from infected individuals on suppressive cART. In this
regard, its activity in CD8+-depleted MNC was more robust than
that of SAHA, which is currently being tested in clinical trials for
its potential to reduce or eliminate the latent HIV-1 reservoir.
Importantly, 57704 was found to reactivate latent HIV-1 without
inducing global T cell activation. As such, 57704 serves as the
prototype of a new mechanistic class of agents that could help
purge the latent HIV-1 reservoir. Furthermore, our data validate
PI3K p110a as a target for the discovery of more potent activators
of latent HIV-1 expression.
The PI3K/Akt signaling pathway appears to play a key role in
the maintenance of HIV-1 latency. Indeed, previous studies have
demonstrated that hexamethylene bisacetamide (HMBA) tran-
siently activates this pathway, which leads to phosphorylation of
HEXIM1 and the subsequent release of active positive transcrip-
tion elongation factor b (P-TEFb) from its transcriptionally
inactive complex with HEXIM1 and 7S small nuclear RNA
(snRNA). As a result, P-TEFb is recruited to the HIV-1 promoter
to stimulate transcription elongation and viral production [25].
Similarly, SAHA and other HDAC inhibitors have been shown to
activate this pathway in several subpopulations of T cells,
including memory T cells [16,23]. Importantly, inhibition of
PI3K significantly reduces the latent reactivation activity of
HDAC inhibitors [16,23]. The mechanism by which HMBA
activates the PI3K/Akt pathway is not known. However, in this
study we show that SAHA, like 57704, acts as an agonist of PI3K
p110a. However, unlike 57704, SAHA also shows agonistic
activity toward the other PI3K isoforms. Therefore, 57704 and
SAHA activate the PI3K/Akt signaling pathway via a similar
mechanism of action. However, it should be noted that 57704 is
not an HDAC inhibitor.
The class I PI3Ks include four isoforms consisting of two
subdivisions, namely, class IA (PI3K p110a, b and d) activated by
tyrosine kinases, antigen and cytokine receptors, and class IB
(PI3K p110c) activated by G-protein-coupled receptors [22]. The
class IA isoforms share 42–58% amino acid sequence. PI3K p110c
shares 36% identity with p110a. Despite largely conserved active
sites (they all catalyze the same reaction), isoform specific
inhibitors have been developed to each of the PI3K isoforms
[22]. Interestingly, we found that 57704 shows unique specificity
to PI3K p110a. Its interaction with this isoform and the
mechanism by which it enhances kinase activity are not known,
but warrant further investigation. Similarly, the contribution of
each PI3K isoform in the establishment and maintenance of HIV-
1 latency is not known. In this regard, additional research is
required to determine whether an agonist with broader specificity
to other PI3K isoforms may elicit a more pronounced effect in
reactivating latent HIV-1 expression.
In conclusion, we have discovered that 57704, a novel small
molecule agonist of PI3K p110a, can reactivate latent HIV-1. The
57704 pharmacophore could serve as a scaffold for the develop-
ment of more potent activators of latent HIV-1 that could be used,
possibly in combination with other agents, to induce expression of
the latent reservoir in HIV-1-infected individuals.
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